H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease

Clinical and Experimental Immunology

Volumn 186, Issue 1, 2016, Pages 30-38

  Ruscitti, P ^a   Cipriani, P ^a   Ciccia, F ^b   Di Benedetto, P ^a   Liakouli, V ^a   Berardicurti, O ^a   Carubbi, F ^a   Guggino, G ^b   Di Bartolomeo, S ^a   Triolo, G ^b   Giacomelli, R ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

adult onset Still's disease; dermal immune system; ferritin; hyperferritinaemic syndrome; macrophage

Indexed keywords

C REACTIVE PROTEIN; CD163 ANTIGEN; CD68 ANTIGEN; FERRITIN; FERRITIN HEAVY SUBUNIT; FERRITIN LIGHT SUBUNIT; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FERRITIN BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN INFILTRATE;

EID: 84991229688     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12826     Document Type: Article

References (42)

1. Tay SS, Roediger B, Tong PL et al. The skin-resident immune network. Curr Dermatol Rep 2013; 3:13–22.
2. Marzano AV, Fanoni D, Antiga E et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol 2014; 178:48–56.
3. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity 2011; 35:857–69.
4. Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. Semin Immunol 2015; 27:249–56.
5. Dupasquier M, Stoitzner P, van Oudenaren A et al. Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse dermis. J Invest Dermatol 2004; 123:876–9.
6. Dupasquier M, Stoitzner P, Wan H et al. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. J Leukoc Biol 2006; 80:838–49.
7. Goren I, Allmann N, Yogev N et al. A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am J Pathol 2009; 175:132–47.
8. Mirza R, Di Pietro LA, Koh TJ. Selective and specific macrophage ablation is detrimental to wound healing in mice. Am J Pathol 2009; 175:2454–62.
9. Lucas T, Waisman A, Ranjan R et al. Differential roles of macrophages in diverse phases of skin repair. J Immunol 2010; 184:3964–77.
10. Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol 2015; 33:643–75.
11. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451–83.
12. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. Autoimmun Rev 2014; 13:708–22.
13. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006; 65:564–72.
14. Maria AT, Le Quellec A, Jorgensen C et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 2014; 13:1149–59.
15. Cipriani P, Ruscitti P, Carubbi F et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 2014; 33:49–55.
16. Cozzi A, Papagrigoraki A, Biasi D et al. Cutaneous manifestations of adult-onset Still's disease: a case report and review of literature. Clin Rheumatol 2016; 35:1377–82.
17. Yamamoto T. Cutaneous manifestations associated with adult-onset Still's disease: important diagnostic values. Rheumatol Int 2012; 32:2233–7.
18. Rosário C, Zandman-Goddard G, Meyron-Holtz EG et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013; 11:185.
19. Zandman-Goddard G, Shoenfeld Y. Hemophagocytic syndrome with hyperferritinemia: a stormy immunological response. Isr Med Assoc J 2013; 15:187–8.
20. Recalcati S, Invernizzi P, Arosio P et al. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 2008; 30:84–9.
21. Wang W, Knovich MA, Coffman LG et al. Serum ferritin: past, present and future. Biochim Biophys Acta 2010; 1800:760–9.
22. Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19:424–30.
23. Pouchot J, Sampalis JS, Beaudet F et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991; 70:118–36.
24. + macrophages displays mixed polarizations in discoid lupus skin. Arthritis Res Ther 2015; 17:324.
25. Zhang W, He KF, Yang JG et al. Infiltration of M2-polarized 514 macrophages in infected lymphatic malformations: possible role 515 in disease progression. Br J Dermatol 2016. doi: 10.1111/bjd.14471 [Epub ahead of print].
26. Heier I, Søyland E, Krogstad AL et al. Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin. Br J Dermatol 2011; 165:792–801.
27. D'Elia RV, Harrison K, Oyston PC et al. Targeting the ‘cytokine storm’ for therapeutic benefit. Clin Vaccine Immunol 2013; 20:319–27.
28. Suzuki K, Kimura Y, Aoki M et al. Persistent plaques and linear pigmentation in adult-onset Still's disease. Dermatology 2001; 202:333–5.
29. Sarkar RN, Bhattacharya R, Bhattacharyya K et al. Adult onset Still's disease with persistent skin lesions complicated by secondary hemophagocytic lymphohistiocytosis. Int J Rheum Dis 2014; 17:118–21.
30. Kikuchi N, Satoh M, Ohtsuka M et al. Persistent pruritic papules and plaques associated with adult-onset Still's disease: report of six cases. J Dermatol 2014; 41:407–10.
31. Fortna RR, Gudjonsson JE, Seidel G et al. Persistent pruritic papules and plaques: a characteristic histopathologic presentation seen in a subset of patients with adult-onset and juvenile Still's disease. J Cutan Pathol 2010; 37:932–7.
32. Lee JY, Hsu CK, Liu MF et al. Evanescent and persistent pruritic eruptions of adult-onset still disease: a clinical and pathologic study of 36 patients. Semin Arthritis Rheum 2012; 42:317–26.
33. Wolgamot G, Yoo J, Hurst S et al. Unique histopathologic findings in a patient with adult-onset Still disease. Am J Dermatopathol 2007; 29:194.
34. + cells colonize the lymph nodes of the patients with Adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue. Correlation with disease severity and implication for pathogenesis. Clin Exp Immunol 2016; 183:397–404.
35. Ruscitti P, Cipriani P, Di Benedetto P et al. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmun Rev 2015; 14:429–37.
36. Wei Y, Miller SC, Tsuji Y et al. Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun 1990; 169:289–96.
37. Cohen LA, Gutierrez L, Weiss A et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010; 116:1574–84.
38. Chen TT, Li L, Chung DH et al. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for Hferritin endocytosis. J Exp Med 2005; 202:955e65.
39. Colafrancesco S, Priori R, Alessandri C et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res 2014; 60:177–83.
40. Matsui K, Tsuchida T, Hiroishi K et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxf) 1999; 38:477–8.
41. Jung S-Y, Park Y-B, Ha Y-J et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol 2010; 37:1029–34.]
42. Zou Y-Q, Lu L-J, Li S-J et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult onset Still's disease. Clin Biochem 2008; 41:519–24.